================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 22, 2005
MEDICOR LTD.
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-50442 14-1871462
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File No.) Identification No.)
4560 S. Decatur Boulevard, Suite 300, Las Vegas, Nevada 89103
(Address of Principal Executive Offices)
(702) 932-4560
(Registrant's Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 8.01. OTHER EVENTS.
MediCor Ltd. (the "Company") issued a press release on September 22, 2005. The
press release announced that the Company plans to file for an Investigational
Device Exemption (IDE) with the U.S. Food and Drug Administration (FDA) in the
first quarter of 2006 for high-consistency silicone-filled breast implants. A
copy of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
Exhibit No. Description
----------- --------------------------------------------------------
99.1 Copy of press release issued by the Company on
September 22, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MEDICOR LTD.
By: /s/ Theodore R. Maloney
-------------------------
Name: Theodore R. Maloney
Title: Chief Executive Officer
Dated: September 22, 2005